The FDA has accused Novo Nordisk of creating a "false or misleading" advertisement for its weight loss pill Wegovy. The agency has also sent warning letters to other companies, including Eli Lilly and Hims & Hers, regarding potentially misleading pharmaceutical advertising. The scope of the FDA's actions appears to be broader, with reports of warning letters being sent to 30 companies, although the specifics of the warnings and the companies involved are not entirely clear.